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Abstract
Bacterial cyclic glucans are glucose polymers that concentrate within the periplasm of alpha-proteobacteria. These
molecules are necessary to maintain the homeostasis of the cell envelope by contributing to the osmolarity of Gram
negative bacteria. Here, we demonstrate that Brucella b 1,2 cyclic glucans are potent activators of human and mouse
dendritic cells. Dendritic cells activation by Brucella b 1,2 cyclic glucans requires TLR4, MyD88 and TRIF, but not CD14. The
Brucella cyclic glucans showed neither toxicity nor immunogenicity compared to LPS and triggered antigen-specific CD8+ T
cell responses in vivo. These cyclic glucans also enhanced antigen-specific CD4+ and CD8+ T cell responses including cross-
presentation by different human DC subsets. Brucella b 1,2 cyclic glucans increased the memory CD4+ T cell responses of
blood mononuclear cells exposed to recombinant fusion proteins composed of anti-CD40 antibody and antigens from both
hepatitis C virus and Mycobacterium tuberculosis. Thus cyclic glucans represent a new class of adjuvants, which might
contribute to the development of effective antimicrobial therapies.
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Introduction
Cyclic glucans are intrinsic components of the envelopes of
Gram negative bacteria such as Agrobacterium, Rhizobium, Ralstonia
solanacearum, Xanthomonas campestris, Rhodobacter sphaeroides and
Brucella spp. [1]. Brucellae are intracellular pathogens of mammals,
including humans [2]. The pathogenesis of brucellosis is linked to
the ability of Brucella to survive and replicate inside host cells [3]
through the expression of several effector molecules [2]. In
particular, the periplasmic cyclic glucan is required for B. abortus
intracellular trafficking [4–6] through the recruitment of the raft
protein flotilin-1 at the site of the Brucella-containing vacuole [6].
This polysaccharide is built of a cyclic backbone of 17 to 25
glucose units in b-1,2 linkages (CbG). CbG are abundant as they
represent 1–5% of the bacteria dry weight. If the CbG content of a
single bacterium is released inside a Brucella-containing vacuole, its
concentration in the vacuole can reach 10 mM. The release of
CbG in mM concentration upon bacterial killing through immune
mechanisms [6] might alter the host immune responses.
While linear (1, 3) b-glucans have been shown to elicit anti-
tumor [7,8] and anti-infective [9–12] responses [13,14], we do not
know whether CbG displays immunomodulatory functions. In this
study, we have analyzed the effects of CbG on mouse and human
dendritic cells (DC) and its consequences on immune responses.
The discovery of vaccination is one of most important medical
discoveries in the history and a turning point in the war between
microbes and humans [15,16]. The goal of vaccination is to induce
long-lasting protective immunity from infection and prevent
infectious diseases. Vaccines operate through the activation of
antigen-presenting cells such as DC that eventually stimulate
antigen-specific T and B lymphocytes. Unlike attenuated live
vaccines, killed whole organisms or subunit vaccines generally
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require the addition of adjuvants to be effective. Adjuvants
promote and enhance immune responses to vaccine components
[15,16]. It is now clear that adjuvants activate DC [15]. Adjuvants
derived from microorganisms stimulate DC directly, leading to the
up-regulation of cytokines, MHC class II, and co-stimulatory
molecules and to their migration to the T cell area of lymph nodes.
These pathogen-associated molecular patterns (PAMP) activate
pattern-recognition receptors (PRR), which act as microbial
sensors and are expressed by DC and other leukocytes [13,14].
Most of PAMP used as vaccine adjuvants, like CpG oligonucle-
otides and monophosphoryl lipid A (MPLA), are agonists of Toll-
like receptors (TLR) [17,18]. For infectious as well as for
noninfectious diseases, TLR activation have been used in both
established and experimental vaccines [17,18].
Bacterial components are often potent immune activators
trough commonly associated with toxicity, for example, bacterial
DNA with immunostimulatory CpG motifs that bind TLR-9 are
potent cellular adjuvants. Overall, several hundred natural and
synthetic compounds have been identified to have adjuvant
activity such as microbial products, mineral salts, emulsions,
microparticles, and liposomes. Although many are more potent
than alum, the almost universal human vaccine adjuvant, toxicity
is the limiting step for their use in humans. Consequently there is a
major unmet need for safer and more effective adjuvants suitable
for human use [15–17].
We show here that Brucella CbG is neither toxic nor
immunogenic when compared to LPS. It is a potent activator of
DC thereby triggering antigen-specific CD8+ T cell responses in
vivo. Brucella CbG enhance antigen-specific CD4+ and CD8+ T cell
responses including cross-presentation by different human DC
subsets.
Results
Brucella cgs- mutants are poor inducers of DC maturation
Wild type B. abortus triggers limited activation of mouse bone
marrow-derived dendritic cells (BMDC) [19]. Infection of BMDC
with B. abortus cgs- (cyclic glucan synthase) mutant failed to activate
BMDC as measured by the production of TNF-a and IL-12
(Figure S1A and S1B). Likewise these infected DC displayed a low
expression of immune co-stimulatory molecules such as CD80,
CD83 and CD86 (not shown). This pilot findings led us
hypothesize that CbG indeed acts as a DC activation molecule.
To this end we had to ensure that the CbG preparations would not
be contaminated by the potent DC activators LPS and lipid A.
Whereas CbG are highly soluble in water, B. abortus and B.
melitensis LPS partition in the phenol phase of the classical
Westphal hot water-phenol extraction procedure. Thus, this
extraction method was applied twice to a CbG water extract
previously digested with nucleases and proteinase K. The identity
of the CbG was established by several methods, including 13C-
NMR, and the absence of LPS tested by both conventional
analytical methods (SDS-PAGE, inability to elicit anti-LPS
antibodies, and Kdo analysis). MALDI-TOF analysis further
showed both the spectra expected from Brucella CbG and the
absence of molecular species signalling like Brucella lipid A (Figure
S2A and S2B).
Cyclic glucan activate murine DC
Mouse BMDC were incubated with synthetic methyl-b-cyclo-
dextrin (MbCD) and cyclic glucans purified from Brucella melitensis,
Brucella abortus and Ralstonia solanacearum. Brucella CbG consists of a
cyclic backbone of 17–25 glucose residues linked in b-(1R2)
associated with O-succinyl modifications [20,21]. Ralstonia cyclic
a-glucan (CaG) is composed of 12 glucoses linked in eleven b-
(1R2) plus one a-(1R6) linkages [20]. MbCD consists of 7 O-
methyl substituted glucoses in b-(1R4) linkages. Both B. melitensis
and B. abortus CbG induced DC to express levels of CD80, CD86,
CD40 and MHC II molecules, comparable to those elicited by E.
coli LPS (Figure 1A). The two Brucella CbG induced the secretion
of high levels of pro-inflammatory cytokines such as TNF-a and
IL-12 (Figures 1B). The induction was dose-dependent (Figure
S3A and S3B). These findings contrast with the poor DC-
activating ability of Brucella LPS [2]. When compared to Brucella
abortus CbG, the synthetic MbCD did not stimulate DC
(**p,0.01) and the Ralstonia CaG hardly induced (**p,0.01) the
production of TNF-a and IL-12 (Figure 1B). Thus Brucella melitensis
CbG is a potent activator of mouse DC.
DC activation by CbG requires TLR4, MyD88 and TRIF, but
not CD14
We then asked whether CbG, like LPS would activate DC
through TLR4, MyD88 and TRIF pathways. Thus, BMDC were
derived from TLR42/2, TLR22/2, MyD882/2, TRIF2/2,
TRIF/MyD882/2 and CD142/2 mice. These DC were activated
with either CbG or different TLR agonists such as CpG (TLR9
agonist), Pam2CSK4 (TLR2/6 agonist), curdlan (linear b-1,3
glucan from Alcaligenes faecalis agonist of Dectin-1 [22,23]) and E.
coli LPS (TLR4/MD2/CD14 agonist). Neither E. coli LPS nor B.
melitensis CbG were able to induce the expression of co-stimulatory
molecules (Figure 2A) and secretion of IL-12 (Figures 2B, 2C) by
BMDC from TLR42/2, Myd882/2, Myd88/TRIF2/2 and
TRIF2/2 mice. In addition, transfection of HEK 293T cells with
vectors coding for TLR4/MD2, TLR2, TLR3 and TLR9 showed
that CbG effect is dependent on TLR4/MD2 (not shown).
Moreover, CbG-treated human blood plasmacytoid DC (pDC)
known to be devoid of surface TLR4 expression [24–26] were not
activated by any of these agents (data not shown). These results
show that DC activation by CbG is TLR4-dependent and that DC
activation is dependent on both MyD88 and TRIF adaptors
(Figure 2B, left panel).
We then compared DC activation induced by B. melitensis CbG
to that induced by linear ß1-3 glucans (curdlan), which bind to
Dectin-1 and activate DC in a MyD88/TRIF-independent
manner [22,23]. First, several monoclonal antibodies specific for
Dectin-1 that can inhibit curdlan-mediated activation failed to
inhibit CbG-mediated DC activation (not shown). While double
MyD88/TRIF2/2 BMDC did not respond to CbG (**p,0.01),
they secreted high levels of IL-12 in response to curdlan
(Figure 2C). These results indicate that CbG and curdlan use
Author Summary
Vaccination is one of the key strategies to fight against
infectious diseases though numerous diseases remain
without appropriate vaccines. The challenge is to generate
potent vaccines capable of inducing long-lasting immunity
in humans. Successful vaccines include adjuvants that
enhance and appropriately skew the immune response to
given antigens. The development of new adjuvants for
human vaccines has become an expanding field of
research. Here we show that bacterial cyclic b-glucans
can be used to enhance cellular immunity by activation of
dendritic cells, from both mice and humans. In particular,
Cyclic-b glucans enhance the in vitro memory CD4+ T cell
responses of patients suffering from hepatitis C and
tuberculosis. Thus cyclic-b glucans are new adjuvants,
which might be used in vaccines.
Adjuvant Properties of Bacterial Cyclic Glucans
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different signalling pathways and that Dectin-1 is not the receptor
for CbG.
LPS recognition involves the LPS-binding protein (LBP), the
TLR4/MD2 complex and CD14 [27]. Accordingly, CD142/2
DC did not secrete IL-12 upon exposure to E. coli LPS (Figure 2D).
CD142/2 DC also failed to upregulate co-stimulatory molecules
and MHC-II in response to LPS (not shown). Strikingly, CbG was
able to stimulate CD142/2 DC to secrete IL-12 (Figure 2D).
Altogether, these data show that CbG signalling is dependent on
TLR4 but does not use CD14 as a co-receptor.
Brucella CbG is neither toxic nor immunogenic
LPS displays a toxicity that precludes its use as a vaccine
adjuvant. Previous studies in cell cultures revealed that CbG, when
compared to MbCD was not cytotoxic even at very high
concentrations [6]. In addition, the Limulus Ameobocyte Lysate
(LAL) test showed that CbG preparations did not contain
significant endotoxin levels. To assess CbG toxicity in mice
LD50 (Lethal dose 50%) was determined by injecting increasing
amounts with death being recorded at 12 h, 24 h, 48 h, 72 h post-
injection. Results showed that more than 500 mg of Brucella CbG
were required to kill 50% of mice, when compared to 65 mg of E.
coli LPS.
To determine the immunogenicity of CbG, Balb/C mice were
injected with by PBS, E. coli LPS, B. melitensis LPS or B. melitensis
CbG. Primary and secondary antibody responses were analyzed
and total immuoglobulin levels quantified by ELISA. Unlike E. coli
LPS or B. melitensis LPS, B. melitensis CbG did not induce the
generation of specific antibodies (Figure S4A). We also analyzed
CbG-mediated ability to induce pro-inflammatory cytokines in the
sera of immunized mice by Cytokine Bead Array (CBA) assay
(Figure S4B). C57Bl/6 mice were injected with PBS, CbG,
monophosphoryl-lipid A (MPLA), LPS or Poly I/C. After 6 h,
24 h and 72 h of immunization, mice were bled and cytokine
levels were measured. At 6 h post-immunization CbG, MPLA and
PolyI/C did not induce pro-inflammatory cytokine secretion in
contrast to E. coli LPS (Figure S4B). Altogether, these data show
that Brucella CbG is neither toxic nor immunogenic in mice.
Brucella CbG increases antigen-specific CD8+ T cell
responses in vivo
Given its ability to activate DC and its low toxicity profile we
wondered whether administration of CbG to mice would enhance
antigen-driven cellular immune responses in vivo. We used
transgenic mice (OT-I Rag2/+) that express a CD8+ T cell
population specific for ovalbumin (OVA) as well as a congenic
Ly5.1/Ly5.2 mouse model with 2 allelic forms of CD45. We
transferred CD8+ Ly5.2 CFSE+ OT-I T cells into C57Bl/6 Ly5.1
mice, and immunized them subcutaneously with either OVA
alone, or a mix of OVA with CbG or OVA with Poly I:C or OVA
with MPLA [15]. At day 3 post-immunization, OVA-specific OT-
I T cell proliferation of all immunized mice was detected in the
draining lymph nodes (Figure 3). OVA-specific T cells from mice
immunized with Poly I:C, MPLA and CbG showed an up-
regulation of CD25 and a down-regulation of CD62L, which
correlated with T cell migration from lymph nodes to the sites of
infection. OVA-specific T cells from mice treated with CbG
showed a stronger down-regulation of CD62L expression than
those treated with Poly I:C or MPLA (Figure 3).
At day 6 post-immunization (Figure S5), OVA-specific T cells
from CbG+OVA-immunized mice displayed stronger antigen-
specific OT-I T cell proliferation and activation than those from
mice immunized with OVA alone. Comparable responses were
detected using the three adjuvants (Figure S5). We concluded that
CbG is able to enhance antigen-specific CD8+ T cell responses in
vivo.
To study CbG capacity to induce local inflammation, mice were
immunized either with MPL, LPS, CbG or Poly I/C by skin
intradermal injection. At 48 h post-treatment, both the adjuvant-
treated and untreated ears were collected for histological analysis
of cutaneous inflammation (Figure S6). The skin of adjuvant-
treated mice revealed marked increase in ear thickness accompa-
nied by inflammatory cell infiltration (Figure S6). The inflamma-
tion was observed in all mice immunized with different adjuvants.
Animals developed acute diffuse dermatitis characterized by heavy
neutrophilic infiltration associated with hyperemia of dermal
capillaries with neutrophilic margination and well-developed
edema of the dermis (Figure S6). Similarly to other known
adjuvants, CbG is capable of inducing local inflammation.
Brucella CbG activates human DC subsets
We next analysed whether CbG was able to activate different
human DC subsets (Table 1). We included myeloid DC isolated
from blood, dermis and epidermis [28,29] as well as DC generated
in vitro by culturing monocytes in the presence of GM-CSF with
either IL-4 or IFNa. In response to CbG, all tested DC showed
increased expression of HLA-DR, CD40, CD86, and CD83 and
increased secretion of IL-12, IL-6 and TNF-a (Figures 4 and 5).
Notably, CbG did not activate pDC as measured by cell surface
phenotype and secretion of IFN and pro-inflammatory cytokines
such as TNF-a and IL-12p70.
To eventually distinguish the effects of LPS from those of CbG,
blood mDC from five donors were activated for 6 h with either
LPS or CbG and the early transcriptional responses was assessed
using microarray profiling. 562 transcripts were significantly
modulated in CbG-treated mDC as compared to media controls
(Figure 4A). These genes displayed a similar expression profile in
LPS-treated mDC, albeit with lesser global intensity as measured
by the molecular distance to media. Statistical comparison (Ttest,
p-value 0.01, no correction) between CbG-treated and LPS-
treated mDC yielded 133 differentially regulated transcripts (data
not shown), highlighting the similarities and the differences
between the two stimuli. Ingenuity Pathway Analysis (IPA)
identified DC maturation as the most significantly represented
canonical pathway among genes over-expressed in CbG-treated
mDC (Figure 4B), and PDFG signalling as the most represented
pathway among genes under-expressed in CbG-treated mDC
(Figure 4C). Furthermore, CbG-treated mDC displayed increased
transcription of the co-stimulatory molecules CD40, CD80,
CD86, CD70 and 4-1BBL, but decreased transcription of the
Th2 co-stimulatory molecule OX40-L (Figure 4D). The most
significantly over-expressed transcripts in CbG-treated mDC are
represented as a network (Figure 4E) depicting a strong pro-
inflammatory response network. Overall, the global transcriptional
Figure 1. Induction of mouse BMDC maturation depends on the structure of the cyclic glucan. Mouse BMDC were stimulated for 8 h (in
white) and 24 h (in black) with medium, E. coli LPS, B. melitensis CbG, B. abortus CbG, Ralstonia CaG or MbCD at equivalent molarity (0.25 mM). Surface
levels of MHC-II, CD80, CD40 and CD86 were measured by flow cytometry (A). IL-12 and TNF-a secretion levels in culture supernatant were
determined by ELISA (B). Data are representative of at least three independent experiments.* p,0.05, ** p,0.01.
doi:10.1371/journal.ppat.1002983.g001
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Figure 2. CbG-induced BMDC maturation is TLR4-dependent. (A) BMDC from wild type (white bars) and TLR42/2 (black bars) mice were
stimulated either with E. coli LPS (0.25 mM), B. melitensis CbG (0.25 mM) or Pam2CSK4 (10 ng/ml). Cell maturation was assessed by flow cytometry for
surface co-stimulatory molecule expression (CD40, CD80 and CD83). Data are representative of at least three independent experiments. * p,0.05, **
p,0.01, ns: not significant. (B) Left panel: BMDC from wild type (white bars), MyD882/2 (black bars) and TRIF2/2 (grey bars) mice were treated with
either E. coli LPS (0.25 mM), B. melitensis CbG (0.25 mM), CpG (1 mM) or Poly I:C (50 mg/ml). IL-12 secretion level was measured by ELISA. Right panel:
BMDC from wild type (white bars), TLR42/2 (black bars) and TLR22/2 (grey bars) mice were activated by E. coli LPS (0.25 mM), B. melitensis CbG
(0.25 mM) or Pam2CSK4 (10 ng/ml). IL-12 secretion level was determined by ELISA. Data are representative of at least three independent experiments.
* p,0.05, ** p,0.01. (C) IL-12 secretion level was analyzed in BMDC from wild type (white bars) and MyD88/TRIF2/2 (black bars) mice stimulated by
B. melitensis CbG (0.25 mM) or curdlan (100 mg/ml). Data are representative of at least three independent experiments.** p,0.01. (D) IL-12 secretion
level was analyzed in BMDC from wild type (white bars) and CD142/2 (black bars) mice were stimulated by E. coli LPS (0.25 mM) or B. melitensis CbG
(0.25 mM). Data are representative of at least three independent experiments. ** p,0.01.
doi:10.1371/journal.ppat.1002983.g002
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changes that CbG elicit in mDC support the concept that this
molecule might enhance DC-dependent T cell responses.
CbG activated blood mDC elicit CD8+ T cell priming
We focused our attention to the effects of CbG on human blood
mDC. Like E. coli LPS, CbG increased the surface expression of
CD40, CD83, CD86 and MHC II (Figure 5A). Furthermore,
CbG-treated mDC secreted high levels of IL-6, TNF-a and IL-12
(p40) (Figure 5B) and were efficient at inducing allogeneic naı¨ve
CD4+ and CD8+ T cell proliferation (Figure 5C). E. coli LPS-
activated DC were slightly more potent than CbG-activated DC at
inducing the proliferation of naı¨ve allogeneic T cells (Figure 5C).
DC loaded with heat inactivated influenza virus can cross-
present the Flu MP antigen to CD8+T cells as 0.8–1.38% of
cocultured CD8+ T cells are specific for Flu-MP as assessed using
peptide-MHC Class I tetramers. Activation of the mDC with both
CbG and E. coli LPS resulted in a considerably increased MP-
specific CD8+ T cell response (Figure 5D). This indicates that
CbG can enhance secondary CD8+T cell responses.
To assess whether CbG can enhance the priming of naı¨ve CD8+
T cells by DC, we chose the melanoma-derived antigens MART-1
and gp100. The experiments illustrated in Figures 6A and 6B have
respectively been performed with human skin CD1a+ and CD14+
DC [28]. Priming of naı¨ve CD8+T cells requires activation of the
DC through CD40 and addition of IL-2 and IL-7 to the cultures.
Further activation of DC with LPS or CbG did not enhance the
response to the relatively abundant MART-1 T cells. However,
CbG enhanced the priming to the less frequent gp100-specific
naı¨ve T cells (Figure 6).
Naı¨ve CD8+ T cells were also cultured for seven days with
allogeneic mDC that were activated or not with either LPS or
CbG (Figure 7A). CbG-activated mDC were also capable of
inducing naı¨ve CD8+ T cells to express high levels of IFNc and
granzyme B in CD8+ T cells when compared to unactivated mDC
(Figure 7A).
Thus, CbG-activated mDC are able to activate CD8+ T cells.
Brucella CbG increases CD4+ T memory responses in
PBMC from HCV cured and TB patients
To characterize the CD4+ T cells exposed to CbG activated
mDC, CD4+ T cells were cultured with allogeneic blood mDC
activated or not with either LPS or CbG for seven days (Figure 7B).
The cultured T cells were then restimulated with PMA/
Ionomycin and stained for intracellular IFN-c, IL-13, and IL-17.
Both LPS and B. melitensis CbG-activated mDC polarized CD4+ T
cells into IFN-c-expressing Th1 cells (Figure 7B). In addition, both
E. coli LPS and CbG-activated DC induced a minor sub-
population of naı¨ve CD4+ T cells to differentiate into IL-13+
CD4+ T cells. Naı¨ve CD4+ T cells co-cultured with either E. coli
LPS-activated or CbG-activated mDC did not express IL-17
(Figure 7B). Thus, CbG-activated mDC induce Th1 responses.
DC targeting approach consists in delivering antigens directly to
DC in vivo using chimeric proteins composed of an anti-DC
receptor antibody coupled to a selected antigen [30]. The selection
of the appropriate adjuvant is a critical parameter for the
induction of the desired type of immune response. PBMC from
cured chronic HCV infected patients were cultured for ten days
with monocyte-derived DC and recombinant humanized anti-
CD40 or anti-DCIR fused to the HCVNS3 antigen with or
without CbG or Poly-IC. Antigen-specific responses were mea-
sured by exposing the cultured cells to specific peptides clusters
and stained for intracytoplasmic IFNc expression. Low IFN-c
levels were observed in PBMC cultured with DC and control IgG4
with or without the adjuvants (Figure 8A). Moreover DC targeting
by anti-CD40 and anti-DCIR enhanced IFN-c production by
CD4+ T cells. Potent memory CD4+ T (Figure 8A), but not CD8+
T cell (not shown) responses were observed after DC-PBMC co-
culture in these conditions.
Few CD4+ T cell responses could be induced when anti-CD40
targeted-DC were treated with Poly I:C, as demonstrated by the
presence of some CD3+CD4+IFN-c+ T cell (1.21% of parents cells,
Figure 8A). However, CbG-treated DC using anti-CD40 targeting
induced a dramatic increase of CD3+CD4+INF-c+ cells (3.53% of
parent cells compared to 0.85% without stimulation, Figure 8A).
When anti-DCIR vaccine targeting was used, we could not
observe any difference in CD4+INF-c+ T cell population with or
without stimulation (Figure 8A).
We next studied CbG effect in DC targeting experiments with
PBMC from acute TB patients. For this, we used humanized anti-
CD40 or anti-DCIR antibodies coupled to Ag85BD41-ESAT6-
Rv1980D24 Mycobacterium tuberculosis antigens developed by the
ANRS (French agency of research against AIDS and viral
hepatitis). DC targeting with control IgG4 and the specific
peptides in the presence of adjuvants triggered IFN-c production
by CD4+ T cells (Figure 8B). This induction was increased in the
presence of CbG upon anti-CD40 and anti-DCIR targeting. The
stimulation by Poly I:C slightly enhanced IFN-c production only
upon anti-DCIR targeting (Figure 8B).
Taken together, these data show that Brucella CbG increases
CD4+ T memory responses after DC targeting of PBMC in HCV
cured and acute TB patients.
Figure 3. B. melitensis CbG induces cellular and responses in vivo. The capacity of Brucella CbG to induce OVA-specific CD8+ T cell responses
was evaluated. CD8+ Ly5.2 CFSE+ T cells were transferred intravenously (i.v.) into naive congenic C57Bl/6 Ly5.1 recipient mice (n = 10). At 24 h,
recipient mice were immunized subcutaneously (s.c.) either with 30 mg OVA in endotoxin free PBS or 30 mg OVA mixed with 200 mg of CbG or 30 mg
OVA mixed with 50 mg poly I:C (Sigma) or 30 mg OVA mixed with 20 mg MPLA (InvivoGen). At day 3 post-immunization, the OVA-specific OT-I T cell
activation in the draining popliteal lymph nodes of immunized mice was investigated by analyzing the up-regulation of CD25 and the down-
regulation of CD62L by flow cytometry. The median fluorescence for each marker is indicated under histograms. Endogenous CD8+ T cell population
(in grey). Data are representative of one experiment among three different experiments.
doi:10.1371/journal.ppat.1002983.g003
Table 1. Different human DCs subsets activation by B.
melitensis CbG.
DC subset DC activation
Blood mDC +++
Blood pDC 2
IL-4 DC ++
IFNa DC ++
Skin CD1a+ DC +++
Skin CD14+ DC +++
B. melitensis CbG activation effect on different subsets of human DC was dete-
rmined. The phenotype of cell activation was analysed by the up-regulation of
classical activation markers at the cell surface (HLA-DR, CD40, CD86, and CD83)
and the secretion of pro-inflammatory cytokines (IL-12, IL-6 and TNF-a).
doi:10.1371/journal.ppat.1002983.t001
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Discussion
Vaccination represents the most effective strategy to combat
infectious diseases. Vaccines are composed of antigens and
adjuvants, which activate antigen-presenting cells which then
triggers the activation, differentiation and expansion of antigen-
specific T and B lymphocytes [15,31–33]. The number of
approved adjuvants effective in humans is very limited since they
are mostly based on alum and on emulsions. Ideally, adjuvants
should elicit a selected immune response (i.e. cellular or humoral
Figure 4. B. melitensis CbG induces over-expression of mRNA transcripts linked to DC maturation and T cell activation in human
blood mDC. (A) Transcripts significantly over/under expressed 2-fold in mDC activated 6 h in vitro with CbG (5 donors, data normalized to 6 h
activation with media control per donor). (B) Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) for genes over-expressed in CbG-
activated mDC. (C) Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) for genes under-expressed in CbG-activated mDC. (D) Bar
charts representing the mean normalized log ratio expression of T cell costimulatory molecules mRNA in mDC activated for 6 h with media (n = 5),
LPS (n = 4) or CbG (CG) (n = 5). Bars represent the standard deviation. (E) Top transcriptional network identified by IPA for genes over-expressed in
CbG-activated mDC. Increase in color intensity represents increase in fold-change compared to 6 h media control treatment. ***p,0.001, **p,0.01,
*p,0.05.
doi:10.1371/journal.ppat.1002983.g004
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immunity depending on the requirements for protection), be safe
(sufficiently immunogenic, without excessive inflammation) and
cost-effective [16,18,31]. The benefits of adjuvant incorporation
into any vaccine formulation should significantly outweigh the
risks of adverse reactions. Unfortunately, potent adjuvant action is
often correlated with increased toxicity, as exemplified by Freund’s
complete adjuvant or LPS. Thus, one of the major challenges in
human adjuvant development is to identify compounds that
enhance vaccine antigen induced responses with maximum
tolerability and safety [31]. In particular, there is a high demand
for adjuvants that stimulate cellular immunity [15,16,18]. Here,
we demonstrate that Brucella CbG is a non-immunogenic and non-
toxic molecule capable of triggering the activation of cellular
responses in vivo. Moreover, Brucella CbG dramatically increases
specific memory CD4+ T cell responses of human PBMC induced
by DC-targeting fusion proteins expressing either HCV antigens
or Mycobacterium tuberculosis antigens. Based on these data, we
propose that Brucella CbG is a candidate adjuvant that might be
used in humans.
There has been an interest to identify TLR4 agonists with a
dampened toxicity. A recent example of lipid A analog is MPLA
known to activate immune cells with similar properties of the LPS
but less toxic and non immunogenic [34,35]. Our results show that
CbG-induced DC maturation is dependent on TLR4 as well as
Myd88 and TRIF adaptor molecules. While CbG activates all
human mDC subsets, it does not activate pDC, which is consistent
with their lack of TLR4 [24–26]. However, what differentiates
CbG from MPLA and Ploy I:C is that CbG induces an early
immune response (Figure 3). This might have a significant impact
on the quality of the immune response to vaccines [36].
We previously showed that Brucella CbG is capable of
interacting with lipid rafts and modulate their organization [6].
Lipid rafts are plasma membrane microdomains enriched in
cholesterol and sphingomyelin that are involved in intracellular
signalling and membrane transport. In particular, lipid rafts are
involved in the regulation and activation of several important
immune receptor complexes such as the TLR4 complex [37]. [38].
It is thus possible that Brucella CbG triggers TLR4-dependent
signalling through its effect on cholesterol in lipid rafts as it has
been suggested for alum [15]. Indeed, alum recognition may occur
indirectly through the release of endogenous uric acid. Recently, it
was shown that monosodium urate crystals activate DC by
interacting with the cell membrane, which leads to plasma
membrane lipid sorting probably via interaction with cholesterol
[15].
Herein, we observed that in contrast to E. coli LPS [27], Brucella
CbG-induced BMDC maturation was independent of the GPI-
anchored protein CD14. Actually, the synthetic lipid A compound
CRX-527 does not require CD14 to engage MyD88-dependent
and TRIF/IRF3-dependent pathways downstream TLR4 [39].
Furthermore, the uropathogenic E. coli (UPEC) triggers innate
responses during urinary tract infection in a TLR4-dependent and
CD14-independent manner both in mice and humans [40]. These
results clearly indicate that CD14 is not required for TLR4-
dependent cell activation. The detailed signalling pathway
involved in CbG-dependent cell activation will require further
studies including the discovery of putative co-receptors associated
to TLR4. Until now, we know that neither dectin-1 nor TLR2
contribute to the activation. Additional studies are planned to
determine whether the CD14-independent CbG-dependent DC
activation will have any therapeutic value.
CbG displays interesting properties such as water solubility,
limited toxicity and lack of immunogenicity together with a potent
DC activation capacity that can trigger CD4+ and CD8+ T cell
responses. Therefore, CbG might constitute a new class of
adjuvants for future vaccines.
Materials and Methods
Ethics
Animal experimentation was conducted in strict accordance with
good animal practice as defined by the French animal welfare bodies
(Law 87–848 dated 19 October 1987 modified by Decree 2001-464
and Decree 2001-131 relative to European Convention, EEC Directive
86/609). INSERM guidelines have been followed regarding animal
experimentation (authorization No. 02875 for mouse experimentation).
All animal work was approved by the Direction De´partmentale des
Services Ve´te´rinaires des Bouches du Rhoˆnes (authorization number
13.118). For animal exerimentation in Costa Rica, animals were
handled and sacrificed according to the approval and guidelines
established by the ‘‘Comite´ Institucional para el Cuido y Uso de los
Animales’’ of the Universidad de Costa Rica, and in agreement with the
corresponding law ‘‘Ley de Bienestar de los Animales No 7451’’ of
Costa Rica (http://www.micit.go.cr/index.php/docman/doc_details/
101-ley-no-7451-leyde-bienestar-de-los-animales.html). The animal
handling and procedures were in accordance with the current
European legislation (directive 86/609/EEC) supervised by the Animal
Welfare Committee of the institution (protocol number R102/2007).
Patients were recruited at the Baylor Hospital Liver transplant
Clinic (BHLTC, Dallas, TX) after obtaining informed consent.
The study was approved by the Institutional Review Board of the
Baylor Health Care System (Dallas, TX).
Reagents
Antibodies used for immunofluorescence labelling included
rabbit Rivoli antibody against murine I-A [41]. CpG (Invivogen),
Pam2CSK4 (Invivogen) and curdlan (Megazyme) were used to
activate DC. Antibodies used for flow cytometry included APC-
CD11c, FITC-CD40, FITC-CD80, PE-CD86, PE-IA-IE (MHC
class II) (Pharmingen), as well as PB-CD8, A700-CD45.2, APC-
CD44, PE-Cy7-CD25, APC-CD62L (BD Biosciences and eBios-
ciences). The Aqua Dead Cell Stain (Invitrogen) was used to
eliminate dead cells. Human mDC were sorted from PBMC of
blood from healthy donors using lineage cocktail-FITC (BD
Biosciences), CD123-PE (BD Biosciences), CD11c-APC (Biole-
gend), HLA-DR-Quantum Red (Sigma). Human mDC were
stained with CD86-PE, CD83-FITC, CD40-APC and HLA-DR-
PB (eBiosciences or Biolegends). 7-AAD was used to exclude dead
cells. For intracellular labelling IL13-APC, INF-c-PE-Cy7, IL-17-
PE and Granzyme B-APC antibodies were used. Isotype matched
Figure 5. B. melitensis CbG-treated human blood mDC enhance CD4+ and CD8+ T cell responses. mDC were stimulated overnight with cell
culture medium, 0.25 mM of E. coli LPS or 0.25 mM of B. melitensis CbG. Surface expression of HLA-DR, CD83, CD40 and CD86 was quantified by flow
cytometry (A). Cytokine levels in culture supernatants were measured by Luminex (B). Experiments were performed on 4 different donors. The data
for one representative are shown. * p,0.05, ns: not significant. (C) CFSE-labeled allogeneic naı¨ve CD4+ T and CD8+ T cells were co-cultured with mDC
for 7 days. Cell division was assessed by CFSE-dilution assay. Experiments were performed on 4 different donors. The data for one representative in
triplicates are shown. (D) Autologous CD8+ T cells were co-cultured with mDC loaded with heat-inactivated influenza virus (PR8) for 7 days. Cells were
stained with anti-CD8 antibody and Flu-M1 tetramer. Experiments were performed on 4 different donors. The data for one representative in triplicates
are shown.
doi:10.1371/journal.ppat.1002983.g005
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Figure 6. B. melitensis CbG-treated human skin DC enhance gp100-specific naı¨ve CD8+T cell priming. (A) CD1a+ skin DC were stimulated
overnight with cell culture medium, 0.25 mM of E. coli LPS or 0.25 mM of B. melitensis CbG and loaded with either MART-1 26–35 (27 L) peptides or
gp100 peptide. Skin DC were then co-cultured wih autologous CD8+ T cells for 10 days in the presence of IL-2 and IL-7. Cells were stained with anti-
CD8 antibody and tetramers. Experiments were performed on 4 different donors. The data for one representative in triplicates are shown. (B) CD14+
skin DC activated by either medium or E. coli LPS or B. melitensis CbG and loaded with either MART-1 26–35 (27 L) peptides or gp100 peptide.
Autologous CD8+ T cells were co-cultured with these DC for 10 days in the presence of IL-2 and IL-7. Cells were stained with anti-CD8 antibody and
tetramers. Experiments were performed on 4 different donors. The data for one representative in triplicates are shown.
doi:10.1371/journal.ppat.1002983.g006
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controls were used appropriately. At least 100.000 events were
collected on flow cytometry Canto II (BDBiosciences) or
FACSAria (BDBiosciences). Flow cytometry analysis was per-
formed using the FlowJo software. Purified cyclic glucans were
obtained from B. melitensis 16 M or Brucella abortus 2308 [42] and
from Ralstonia solanacearum (gift from Dr. J.-P. Bohin, CNRS
UMR8576, Lille, France. Cells were stimulated with 100 ng/ml of
E. coli LPS and 10 mg/ml of B. melitensis CbG to have the
equivalent molarity of reagents (0.25 mM).
Mice and cells
CD-1 and C57Bl/6 Ly5.1 mice from Jackson Laboratory and
OT-I TCR transgenic Ly5.2 mice on C57Bl/6 background were
used. C57BL/6, TLR42/2, TLR22/2, MyD882/2, TRIF2/2,
MyD88/TRIF2/2 mice were maintained at CIML animal house,
France. CD142/2 mice were obtained from CDTA, Orleans,
France. All mice were from a C57BL/6 genetic background.
Mouse bone marrow-derived DC (BMDC) and macrophages
(BMDM) were prepared from 7–8 week-old female C57BL/6
mice as previously described [43].
Human DC
Human monocyte-derived DC were generated from Ficoll-
separated PBMC from healthy volunteers [44]. Monocytes were
enriched from the leukopheresis according to cellular density and
size by elutriation as per manufacturer’s recommendations. For
DC generation, monocytes were resuspended in serum-free
Cellgro DC culture supplemented with 100 ng/ml GM-CSF and
500 UI/ml IFN-a. mDC (HLA-DR+CD11c+CD1232Lin2) and
pDC (HLA-DR+, CD11c2, CD123+, Lin2) were sorted from
fresh PBMC using FACSAria cytometer (BD Biosciences). Naı¨ve
CD4+ and CD8+ T cells (CD45RA+CD45RO2CCR7+) (puri-
ty.99.2%) were purified by flow cytometry sorting.
Brucella CbG extraction, purification and characterization
CbG were obtained from B. melitensis 16 M or B. abortus 2308
grown and inactivated as described before [42]. For CbG
extraction and purification, the protocol described before [6]
was used. Briefly, a CbG-rich crude fraction was first obtained by
ethanol precipitation of a hot water extract of killed bacteria, and
freed from nucleic acids or proteins by digestion with DNase and
RNase proteinase K. To remove LPS, the fluid was extracted with
a volume of phenol (in contrast to most LPS, Brucella LPS and lipid
A partition into the phenol phase [42] at 70uC for 30 min, the
mixture chilled and centrifuged (80006 g, 0uC, 15 min), and the
aqueous phase collected and re-extracted again with phenol under
the same conditions. The new aqueous phase was dialyzed,
clarified by brief centrifugation and freeze-dried. The identity of
CbG was demonstrated by 13C-NMR spectroscopy and high-
performance TLC, and the absence of Brucella LPS or other
contaminants was demonstrated by UV-spectrophotometry, SDS-
PAGE, gel immunoprecipitation, and 3-deoxy-D-manno-2-octulo-
sonic acid analyses [42]. To further demonstrate the absence of
lipid A, purified CbG were analyzed by MALDI-TOF mass
spectrometry as described before [45]. Briefly, 5 mg of lyophilized
Brucella’s CbG were resuspended in 100 ml of chloroform-
methanol-water (3:1.5:0.25 [vol/vol/vol]) and 1 ml aliquot of was
deposited on the target and covered with the same amount of 2,5-
dihydroxybenzoic acid matrix (Sigma) dissolved in chloroform-
methanol-water (3:1.5:0.25 [vol/vol/vol]). Different ratios be-
tween the samples and dihydroxybenzoic acid were used.
Alternatively, matrix solution was prepared by dissolving 1 mg
of 2,5-dihydroxybenzoic acid with 0.1 ml of CH3CN/H2O (3:2,
vol/vol). Analyses were performed in reflector modes and in both
the positive and the negative ion modes on a Bruker Autoflex II
MALDI-TOF mass spectrometer (Bruker Daltonics, Inc.). A
peptide calibration standard (Bruker Daltonics) was used to
calibrate the MALDI-TOF. Spectra were recorded between
1900 and 3900 Da. Each spectrum was an average of 500 shots.
Mark the absence of the ion species at m/z 2073, 2145, 2173 that
are characteristic of Brucella lipid A [46].
Cyclic glucan toxicity and immunogenicity assays
LAL (Limulus ameobocyte lysate) test was used for the detection
and quantification of bacterial endotoxins. Briefly, the samples
were incubated with the circulating blood of horseshoe crab (the
LAL) and a synthetic color producing substrate to detect
endotoxins. LAL contains enzymes that are activated in a series
of reactions in the presence of endotoxins. This assay is
quantitative and the color intensity developed upon addition of
the sample to the LAL is proportional to the amount of endotoxin
in the sample and can be calculate from a standard curve.
Immunogenicity of purified CbG was tested in mice and rabbits
following described protocols [47]. LD50 (Lethal dose 50%) was
measured in CD-1 mice injected with appropriate amounts of
reagents. Animal death was recorded at 12 h, 24 h, 48 h, and
72 h post-injection. To determine the immunogenicity of B.
melitensis CbG, Balb/C mice were immunized by either PBS or E.
coli LPS, (10 mg/mouse) or B. melitensis LPS (10 mg/mouse) or B.
melitensis CbG (10 mg/mouse). The primary antibody response was
measured 21 days after immunization. Mice were boosted 45 days
with the same molecules (5 mg/mouse) to measure the secondary
antibody response. Antibody responses were determined by an
indirect ELISA.
mRNA extraction and hybridization
After culture, human mDC were lysed in RLT buffer and stored
at 280uC until further processing. Total RNA was extracted using
the mirVana miRNA Isolation Kit, from Ambion. Following RNA
extraction, RNA concentration was measured using a Nanodrop
1000 (Nanodrop Technologies, Wilmington, DE) and the RIN was
measured with an Agilent 2100 Bioanalyzer (Agilent, Palo Alto,
CA) for quality control purposes. All samples with RIN values
greater than seven were retained for further processing. 250 ng of
total RNA were amplified and labelled with the Illumina
TotalPrep-96 RNA amplification kit (Ambion, Austin, TX).
750 ng of amplified labelled RNA were hybridized overnight to
Illumina HT12 v4 Beadchip arrays (Illumina, San Diego, CA).
Following hybridisation, each chip was washed, blocked, stained
and scanned on an Illumina iScan following the manufacturer’s
protocol. The dataset described in this manuscript is deposited in
the NCBI Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo, GEO Series accession number GSE32023).
Figure 7. B. melitensis CbG induces the synthesis of effector molecules in human T cells. Human blood mDC were co-cultured with
allogeneic naı¨ve CD4+ T and CD8+ T cells. After 7 days, cells were incubated for 6 h with PMA/Ionomycin in the presence of brefeldin A. The
intracellular levels of IFN-c and granzyme B in CD8+ T cells (A) and IFN-c, IL-13 and IL-17 in CD4+ T (B) and were analysed by flow cytometry.
Experiments were performed on 4 different donors. The data for one representative are shown.
doi:10.1371/journal.ppat.1002983.g007
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Microarray analysis
Transcripts present in at least one of the samples as defined by
significant chip detection value were used as a starting list. Non-
parametric test was applied between CbG-treated mDC and
medium-treated mDC from 5 donors, false discovery rate: 0.01,
with Benjamini-Hochberg correction. Pathway analysis was
conducted with Ingenuity Pathway Analysis (IPA) software,
Ingenuity Systems, Inc, Redwood City, CA. The molecular
distance to medium (MDTM) quantifies the global transcriptional
perturbation of a group of transcripts in a specific sample as
compared to its reference control(s). It is calculated as follows. For
an arbitrary list of transcripts normalized to their reference
control(s), the absolute fold changes greater or equal to 2 for a
specific sample are summed up.
Cytokine measurement
Murine IL-12 and TNF-a were quantified in culture superna-
tants of stimulated DC by sandwich enzyme-linked immunosor-
bent assays (ELISA) according to the manufacturer’s protocol
(Abcys). Human cytokine (IL-6, TNF-a, and IL-12p40) were
determined using the BeadLyte cytokine assay kit (Upstate, MA).
Cytometric Bead Array (CBA) assay
Mice were divided into groups each of 5 mice and were
immunized i.p. with either: 50 ml of PBS, 20 mg of Monophosphoryl
Lipid A (MPLA) (InvivoGen) in 50 ml of PBS, 200 mg of CbG in
50 ml of PBS, 10 mg of LPS in 50 ml of PBS, 50 mg of Poly I/C in
50 ml of PBS. For in vivo cytokine measurements, mice were bled
submandibularly at 6 h, 24 h and 72 h after immunization and sera
collected. Supernatants were then harvested at each time point and
kept at220uC. To determine the amounts of cytokines produced in
the sera, a CBA assay (BD Biosciences) that detects IL-6, IL-10,
MCP-1, IFN-c, TNF-a and IL-12p70 in a single sample was used.
The sera from immunized mice were incubated with a mixture of
specific capture antibodies that were coupled to the beads
containing specific amounts of PE fluorescence intensity. The 6
different fluorescence intensities of PE were detected by flow
cytometry and cytokine concentration in the samples was quantified
from a standard curve according to manufacturer’s protocol. 10.000
events were analyzed by flow cytometry Canto II (BDBiosciences)
and the data were analyzed using the FlowJo software.
Human CD4+ and CD8+ T cell responses
Blood mDC were co-cultured with CFSE-labeled allogeneic
naı¨ve CD4+ T and CD8+ T cells. The expression of intracellular
cytokines and granzyme B were measured after 6 h of cell
stimulation by PMA and Ionomycine, in the presence of Brefeldin
A. Blood mDC from HLA-A0201+ healthy donors were loaded
with a multiplicity of infection (MOI) of 0.2 of heat-inactivated
influenza virus (PR8) for 2 h at 37uC. Autologous CD8+ T cells
were mixed and cultured for 7 days in the presence of 20 units/ml
IL-2. Cells were then stained with anti-CD8 antibody and
tetramer (HLA-A*0201-Flu M158–66). MART-1-specific CD8
+ T
cell responses were measured after co-culturing with CD1a+ and
CD14+ skin DC loaded with 10 mM 15-mer MART-1 peptide-
containing the immunodominant epitope MART-126–35 (27L) or
with gp100 peptide epitope for 10 days. Skin DC were purified as
previously described [28]. To activate individual DC subsets we
used 0.25 mM of either E. coli LPS or CbG.
Autologous IFNa DC loaded with vaccine candidates (for
Mycobacterium: ESAT6 protein, for HCV: antigens from NS3
Helicase helB construct) were co-cultured with PBMC from HCV
or TB patients and incubated for 10 days. T-cell specific responses
elicited by vaccine candidate loaded-DC were assessed by
restimulating PBMC with peptide clusters
Adoptive transfer of OT-I T cells and immunization
OT-I transgenic cells that express TCR specific for an H-2Kb
restricted CD8+ T cell epitope from OVA were used. Lymph
nodes from OT-I Ly5.1 mice were harvested and digested with
collagenase type I (Sigma) at 37uC for 30 min. CD8+ T cells were
then negatively sorted by using mouse CD8 negative isolation kit
(Dynal). CD8+ T cells were labeled with 10 mM CFSE (Invitrogen)
and transferred intravenously (i.v.) into naive congenic C57Bl/6
Ly5.2 recipient mice. At 24 h, recipient mice were immunized
subcutaneously (s.c.) either with 30 mg OVA (EndoGrade) alone in
endotoxin free PBS or 30 mg OVA mixed with 200 mg of CbG or
30 mg OVA mixed with 50 mg poly I:C (Sigma) or 30 mg OVA
mixed with 20 mg MPLA (InvivoGen).
Histology
For histological assessment of cutaneous inflammation, intrader-
mal injection of mouse ear skin was performed. C56BL/6 mice were
immunized in the right ear with either: 20 mg of Monophosphoryl
Lipid A (MPL) in 10 ml of PBS, 200 mg of CbG in 10 ml of PBS,
10 mg of LPS in 10 ml of PBS, 50 mg of Poly I/C in 10 ml of PBS.
PBS was injected in the left ear as negative control. The animals were
sacrificed 48 h later and both the adjuvant-treated and untreated
ears were collected for further determination. Ears were fixed in 10%
neutral buffered formalin for 48 h, embedded in paraffin, then
sectioned at 4 mm at two levels separated by 1 mm interval and
stained with hematoxylin and eosin. Normal skin histology was
evaluated in PBS-inoculated contralateral ear for each mouse.
Statistical analysis
All experiments were carried out at least 3 independent times
and all the results correspond to the means 6 standard errors.
Statistical analysis was done using two-tailed unpaired Student’s t
test. Significance was defined when P values were ,0.05.
Supplementary material
See legends of Figures S1, S2, S3, S4, S5 and S6.
Figure 8. B. melitensis CbG potentiates CD4+ T memory responses in HCV and TB patients. (A) CbG induces CD3+CD4+IFNc+ T cells after
anti-CD40 HCV-NS3HelB DC-targeting of PBMC in HCV cured patients. HCV antigens from NS3 Helicase HelB construct were delivered to IFNa DC
through anti-CD40 or DCIR-Ig4 humanized recombinant antibodies. IFNa DC were targeted with anti-CD40-NS3HelB (5 nM), anti-DCIR-NS3HelB
(5 nM) or Ig4 control antibody (5 nM) in the presence of Poly I:C (25 mg/ml) or CbG (10 mg/ml) before co-culture for 10 days with PBMC from chronic
HCV-infected patients cured after IFNa-Ribavarin therapy. Cells were stimulated for 6 h with peptide clusters (10 mM; 10 peptides of 15-mers)
covering HCV NS3 HelB constructs. PBMC were stained for measuring the frequency of peptide-specific CD3+CD4+IFNc+ T cells and analyzed by flow
cytometry. (B) CbG increases CD4+T cell memory responses induced by anti-CD40 or anti-DCIR coupled to Ag85BD41-ESAT6-Rv1980D24 antigens in
PBMC from TB patients. IFNa DC were loaded on with IgG4 humanized recombinant mAb Ag85BD41-ESAT6-Rv1980D24 (1 pM) either in the presence
of medium versus Poly I:C (2.5 mg/ml) or CbG (1 mg/ml). After 10 days of co-culture with PBMC from acute TB patients, cells were re-stimulated with
peptides at 2.5 mM covering the entire ESAT6 protein (22 peptides of 15–16 mers) for 6 h and the magnitude of the immune recall response in terms
of the percentage of CD3+CD4+IFNc+ T cells was analyzed by flow cytometry.
doi:10.1371/journal.ppat.1002983.g008
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Supporting Information
Figure S1 Bone marrow-derived murine dendritic cells
infected with cgs- mutant display a low maturation
profile. Mouse DC were infected for 24 h with Salmonella
thyphimurium S12023 virulent strain, Brucella abortus 2308 virulent
strain or isogenic cgs- B. abortus mutant. (A, B) IL-12 and TNFa
levels in supernatant were measured by ELISA after infection,
respectively. Data represent means 6 standard errors of at least 3
independent experiments. *p,0.05 cgs- mutant compared to the
wild type values, ns: not significant.
(EPS)
Figure S2 MALDI-TOF mass spectrometry analysis of
CbG preparations. The spectra show six main signals at m/z
2,795, 2,957, 3,119, 3,268, 3,444, and 3,607 consistent with those
expected for CbG molecules composed of 17–22 glucose residues,
as previously described. (A) Positive-ion MALDI-TOF MS. (B)
Negative-ion MALDI-TOF MS. Mark the absence of the ion
species at m/z 2073, 2145, 2173 that are characteristic of Brucella
lipid A.
(EPS)
Figure S3 B. melitensis CbG induces mouse DC matu-
ration in a dose-dependent manner. (A) Mouse DC were
stimulated for 8 h (white) and 24 h (black) with medium, E. coli
LPS (0.25 mM) or B. melitensis CbG (0.025 mM, 0.25 mM, 2.5 mM).
MHC II, CD80, CD40 and CD86 surface levels were analyzed by
flow cytometry. Graphs represent median of fluorescence 6
standard error of four independent experiments. (B) Mouse DC
were treated in triplicate for 8 and 24 h with either medium, E. coli
LPS (0.25 mM) or B. melitensis CbG (0.025 mM, 0.25 mM, 2.5 mM).
IL-12 and TNFa levels in the supernatants were measured by
ELISA. Data represent means 6 standard errors of at least 3
independent experiments. *p,0.05., ns: not significant.
(EPS)
Figure S4 B. melitensis CbG is not immunogenic in
mice. (A) Balb/C mice were immunized by either PBS or E. coli
LPS, (10 mg/mouse) or B. melitensis LPS (Brucella LPS, 10 mg/
mouse) or B. melitensis CbG (CbG, 10 mg/mouse). The primary
antibody response (white bars) was measured 21 days after
immunization. Mice were boosted 45 days with the same
molecules (5 mg/mouse) to measure the secondary antibody
response (black bars). 3 independent experiments were performed
(n = 5), *p,0.05. (B) Levels of pro-inflammatory cytokines are
strongly reduced in the sera of CbG-immunized mice. C57Bl/6
mice (n = 5) were immunized either with PBS, MPL, CbG, LPS or
Poly I/C. After 6 h, 24 h and 72 h of immunization, mice were
bled and the cytokine levels were measured in the sera by CBA.
The levels of IL-6, IL-10, MCP-1, IFNc, TNFa and IL-12p70 are
presented. Data represent means 6 standard errors from 5
samples. ***p,0.001, **p,0.01.
(EPS)
Figure S5 B. melitensis CbG induces cellular immunity
in vivo. CD8+ Ly5.2 CFSE+ T cells were transferred intravenously
(i.v.) into naive congenic C57Bl/6 Ly5.1 recipient mice. 24 h after
OT-I adoptive transfer, recipient mice were immunized subcuta-
neously (s.c.) either with PBS (grey) or 30 mg OVA in PBS or 30 mg
OVA mixed with 200 mg of CbG or 30 mg OVA mixed with 50 mg
Poly I:C or 30 mg OVA mixed with 20 mg MPLA. At day 6 post-
immunization, the OVA-specific OT-I T cell activation in the
draining popliteal lymph nodes of immunized mice was investigated
by analyzing the up-regulation of CD25 and the down-regulation of
CD62L by flow cytometry. The median fluorescence for each
marker is indicated under histograms. Endogenous CD8+ T cell
population (in grey). Data are representative of one experiment
among three different experiments.
(EPS)
Figure S6 CbG triggers a local skin inflammation. Mice
were immunized either with PBS, MPL, CbG, LPS or Poly I/C.
At 48 h post-treatment, both the adjuvant-treated and untreated
ears were collected for histological analysis of cutaneous
inflammation. Hematoxylin- and eosin-stained sections of adju-
vant-immunized mice revealed marked increase in ear thickness
accompanied by inflammatory cell infiltration.
(TIF)
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